Nu Skin Enterprises Reports Fourth Quarter and 2022 Financial Results
Company Provides Initial Outlook for Q1 and FY 2023
Executive Summary
Q4 2022 vs.
Revenue: |
• (7)% FX impact or |
Earnings Per Share |
|
Customers: |
1,147,124; (16)% |
Paid Affiliates: |
236,956; (13)% |
Sales Leaders: |
48,737; (21)% |
Executive Summary
2022 vs. 2021
Revenue: |
• (5)% FX impact or |
Earnings Per Share |
|
"We made steady progress toward our Nu Vision 2025 strategy, despite persistent macro-economic challenges, which primarily included COVID-related disruptions in Mainland China, global inflation and foreign currency headwinds," said
"Looking ahead, while the macro-environment remains uncertain, we expect it to steadily improve throughout the year. We remain confident in our Nu Vision 2025 strategy to help drive long-term growth and increase shareholder value, which we will update on our earnings call today. During the year, we will be advancing our EmpowerMe personalized beauty and wellness strategy by introducing our body iO smart, connected device system and rolling out our TRMe® weight management line. We will also continue to enhance our Vera and Stela apps with additional capabilities, features and improvements to streamline the overall user experience. In addition, as we continue to expand our affiliate-powered social commerce model, we will focus on stabilizing performance in more challenged regions and leveraging best practices from our markets that are further along in their social commerce transition. Lastly, as we navigate the year ahead, we will continue to be conservative in our guidance and prudent in our cost management while we invest in our future."
Q4 2022 Year-over-year Operating Results
Revenue: |
• (7)% FX impact or |
Gross Margin: |
71.7% compared to 74.2% or 75.2% excluding restructuring and • Impacted by geographic footprint, foreign currency and • |
Selling Expenses: |
38.5% compared to 39.1% • |
G&A Expenses: |
24.4% compared to 24.4% |
Operating Margin: |
5.3% or 8.8% excluding restructuring and impairment charges, |
Other Income / |
|
Income Tax Rate: |
(134.9)% or (3.7)% excluding restructuring and impairment charges |
EPS: |
|
Stockholder Value
Dividend Payments: |
|
Stock Repurchases: |
• |
Q1 and Full-year 2023 Outlook
Q1 2023 Revenue: |
• Approximately (6) to (5)% FX impact |
Q1 2023 EPS: |
|
2023 Revenue: |
• Approximately (2) to (1)% FX impact |
2023 EPS: |
|
"Our initial 2023 guidance assumes the global macro environment remains challenging in the near-term, improving throughout the year," said
Conference Call
The
About
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the macro-environment and the company's performance, growth, shareholder value, financial position, strategies, vision, transformation, initiatives, product pipeline and product introductions, digital and social-commerce tools and initiatives, customers, sales leaders, affiliates, and operational improvements; projections regarding revenue, expenses, operating income, earnings per share, foreign currency fluctuations, uses of cash and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "anticipate," "project," "continue," "outlook," "guidance," "remain," "become," "plan," "potential," "expand," "will," "would," "could," "may," "might," the negative of these words and other similar words.
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
- risk that epidemics, including COVID-19 and related disruptions, and other crises could negatively impact our business;
- adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
- risk that direct selling laws and regulations in any of the company's markets, including
the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company's business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events; - any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis;
- political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;
- uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;
- risk of foreign-currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
- uncertainties regarding the future financial performance of the businesses the company has acquired;
- risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
- regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;
- unpredictable economic conditions and events globally;
- the company's future tax-planning initiatives; any prospective or retrospective increases in duties or tariffs on the company's products imported into the company's markets outside of
the United States ; and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and - continued competitive pressures in the company's markets.
The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the
Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It is calculated by translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period's revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company's revenue from period to period.
Earnings per share, gross margin, operating margin, and income tax rate, each excluding restructuring and impairment charges and/or tax method changes, also are non-GAAP financial measures. Restructuring and impairment charges and tax method changes are not part of the ongoing operations of our underlying business. The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of restructuring and impairment charges and tax method changes facilitates period-to-period comparisons of the company's performance. Please see the reconciliations of these items to our earnings per share and other income (expense) calculated under GAAP, below.
The following table sets forth revenue for the three-month periods ended
Three Months Ended |
Constant- |
||||||||||
2022 |
2021 |
Change |
Change |
||||||||
|
|||||||||||
|
$ |
128,921 |
$ |
144,000 |
(10) % |
(7) % |
|||||
Mainland |
73,935 |
130,708 |
(43) % |
(37) % |
|||||||
|
76,606 |
90,313 |
(15) % |
(8) % |
|||||||
|
60,029 |
92,528 |
(35) % |
(26) % |
|||||||
|
53,877 |
63,215 |
(15) % |
6 % |
|||||||
EMEA |
55,337 |
68,066 |
(19) % |
(9) % |
|||||||
|
39,789 |
47,816 |
(17) % |
(10) % |
|||||||
|
1,525 |
156 |
878 % |
876 % |
|||||||
Total |
490,019 |
636,802 |
(23) % |
(15) % |
|||||||
Rhyz Investments |
|||||||||||
Manufacturing |
29,560 |
36,360 |
(19) % |
(19) % |
|||||||
Rhyz other |
2,761 |
274 |
908 % |
908 % |
|||||||
Total Rhyz Investments |
32,321 |
36,634 |
(12) % |
(12) % |
|||||||
Total |
$ |
522,340 |
$ |
673,436 |
(22) % |
(15) % |
The following table sets forth revenue for the years ended
Year Ended |
Constant- |
||||||||||
2022 |
2021 |
Change |
Change |
||||||||
|
|||||||||||
|
$ |
508,537 |
$ |
547,755 |
(7) % |
(5) % |
|||||
Mainland |
360,389 |
568,774 |
(37) % |
(35) % |
|||||||
|
344,411 |
336,651 |
2 % |
7 % |
|||||||
|
268,707 |
354,252 |
(24) % |
(15) % |
|||||||
|
224,896 |
266,216 |
(16) % |
— |
|||||||
EMEA |
204,275 |
283,200 |
(28) % |
(19) % |
|||||||
|
157,197 |
162,611 |
(3) % |
1 % |
|||||||
|
3,959 |
3,653 |
8 % |
8 % |
|||||||
Total |
2,072,371 |
2,523,112 |
(18) % |
(12) % |
|||||||
Rhyz Investments |
|||||||||||
Manufacturing |
149,458 |
172,120 |
(13) % |
(13) % |
|||||||
Rhyz other |
3,830 |
437 |
776 % |
776 % |
|||||||
Total Rhyz Investments |
153,288 |
172,557 |
(11) % |
(11) % |
|||||||
Total |
$ |
2,225,659 |
$ |
2,695,669 |
(17) % |
(12) % |
The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core
Three Months Ended |
|||||||
Customers |
2022 |
2021 |
Change |
||||
|
299,287 |
336,564 |
(11) % |
||||
Mainland |
202,933 |
315,418 |
(36) % |
||||
|
141,183 |
169,601 |
(17) % |
||||
|
123,749 |
146,354 |
(15) % |
||||
|
119,152 |
122,813 |
(3) % |
||||
EMEA |
197,917 |
210,414 |
(6) % |
||||
|
62,903 |
66,395 |
(5) % |
||||
Total |
1,147,124 |
1,367,559 |
(16) % |
||||
Three Months Ended |
|||||||
Paid Affiliates |
2022 |
2021 |
Change |
||||
|
42,633 |
49,328 |
(14) % |
||||
Mainland |
23,436 |
30,546 |
(23) % |
||||
|
38,653 |
44,050 |
(12) % |
||||
|
45,058 |
52,036 |
(13) % |
||||
|
38,021 |
38,428 |
(1) % |
||||
EMEA |
31,869 |
36,482 |
(13) % |
||||
|
17,286 |
20,155 |
(14) % |
||||
Total |
236,956 |
271,025 |
(13) % |
||||
Three Months Ended |
|||||||
Sales Leaders |
2022 |
2021 |
Change |
||||
|
9,594 |
10,879 |
(12) % |
||||
Mainland |
12,359 |
18,207 |
(32) % |
||||
|
6,999 |
8,800 |
(20) % |
||||
|
6,094 |
8,224 |
(26) % |
||||
|
5,936 |
5,864 |
1 % |
||||
EMEA |
4,740 |
5,743 |
(17) % |
||||
|
3,015 |
3,666 |
(18) % |
||||
Total |
48,737 |
61,383 |
(21) % |
(1) The
- "Customers" are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.
- "Paid Affiliates" are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as "Brand Affiliates" because their primary role is to promote our brand and products through their personal social networks.
- "Sales Leaders" are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter.
Consolidated Statements of Income (Unaudited) ( |
|||||||||||
Three Months Ended |
Year Ended |
||||||||||
2022 |
2021 |
2022 |
2021 |
||||||||
Revenue |
$ |
522,340 |
$ |
673,436 |
$ |
2,225,659 |
$ |
2,695,669 |
|||
Cost of sales |
147,816 |
173,775 |
630,915 |
675,223 |
|||||||
Gross profit |
374,524 |
499,661 |
1,594,744 |
2,020,446 |
|||||||
Operating expenses: |
|||||||||||
Selling expenses |
201,031 |
263,265 |
879,634 |
1,080,153 |
|||||||
General and administrative expenses |
127,664 |
164,206 |
555,769 |
654,431 |
|||||||
Restructuring and impairment expenses |
18,370 |
51,870 |
48,494 |
51,870 |
|||||||
Total operating expenses |
347,065 |
479,341 |
1,483,897 |
1,786,454 |
|||||||
Operating income (loss) |
27,459 |
20,320 |
110,847 |
233,992 |
|||||||
Other income (expense), net |
(3,104) |
(1,884) |
(21,877) |
(1,533) |
|||||||
Income before provision for income taxes |
24,355 |
18,436 |
88,970 |
232,459 |
|||||||
Provision (benefit) for income taxes |
(32,860) |
27,666 |
(15,808) |
85,193 |
|||||||
Net income (loss) |
$ |
57,215 |
$ |
(9,230) |
$ |
104,778 |
$ |
147,266 |
|||
Net income (loss) per share: |
|||||||||||
Basic |
$ |
1.16 |
$ |
(0.19) |
$ |
2.10 |
$ |
2.93 |
|||
Diluted |
$ |
1.15 |
$ |
(0.18) |
$ |
2.07 |
$ |
2.86 |
|||
Weighted-average common shares outstanding (000s): |
|||||||||||
Basic |
49,452 |
49,862 |
50,002 |
50,193 |
|||||||
Diluted |
49,783 |
50,801 |
50,525 |
51,427 |
Consolidated Balance Sheets (Unaudited) ( |
|||||
2022 |
2021 |
||||
ASSETS |
|||||
Current assets: |
|||||
Cash and cash equivalents |
$ |
264,725 |
$ |
339,593 |
|
Current investments |
13,784 |
15,221 |
|||
Accounts receivable, net |
47,360 |
41,299 |
|||
Inventories, net |
346,183 |
399,931 |
|||
Prepaid expenses and other |
87,816 |
76,906 |
|||
Total current assets |
759,868 |
872,950 |
|||
Property and equipment, net |
444,806 |
453,674 |
|||
Operating lease right-of-use assets |
98,734 |
120,973 |
|||
|
206,432 |
206,432 |
|||
Other intangible assets, net |
66,701 |
76,991 |
|||
Other assets |
244,429 |
175,460 |
|||
Total assets |
$ |
1,820,970 |
$ |
1,906,480 |
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|||||
Current liabilities: |
|||||
Accounts payable |
$ |
53,963 |
$ |
49,993 |
|
Accrued expenses |
280,280 |
372,201 |
|||
Current portion of long-term debt |
25,000 |
107,500 |
|||
Total current liabilities |
359,243 |
529,694 |
|||
Operating lease liabilities |
76,540 |
88,759 |
|||
Long-term debt |
377,466 |
268,781 |
|||
Other liabilities |
110,425 |
106,474 |
|||
Total liabilities |
923,674 |
993,708 |
|||
Commitments and contingencies |
|||||
Stockholders' equity: |
|||||
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued |
91 |
91 |
|||
Additional paid-in capital |
613,278 |
601,703 |
|||
|
(1,569,061) |
(1,526,860) |
|||
Accumulated other comprehensive loss |
(86,509) |
(73,896) |
|||
Retained earnings |
1,939,497 |
1,911,734 |
|||
Total stockholders' equity |
897,296 |
912,772 |
|||
Total liabilities and stockholders' equity |
$ |
|
$ |
1,906,480 |
|
||||||||||||
Three months ended |
Year ended |
|||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||
Gross profit |
$ |
374,524 |
$ |
499,661 |
$ |
1,594,744 |
$ |
2,020,446 |
||||
Impact of restructuring and impairment: |
||||||||||||
Inventory write-off |
- |
6,656 |
26,905 |
6,656 |
||||||||
Adjusted gross profit |
$ |
374,524 |
$ |
506,317 |
$ |
1,621,649 |
$ |
2,027,102 |
||||
Gross margin |
71.7 % |
74.2 % |
71.7 % |
75.0 % |
||||||||
Gross margin, excluding restructuring impact |
71.7 % |
75.2 % |
72.9 % |
75.2 % |
||||||||
Revenue |
$ |
522,340 |
$ |
673,436 |
$ |
2,225,659 |
$ |
2,695,669 |
|
|||||||||||||
Three months ended |
Year ended December 31, |
||||||||||||
2022 |
2021 |
2022 |
2021 |
||||||||||
Operating Income |
$ |
27,459 |
$ |
20,320 |
$ |
110,847 |
$ |
233,992 |
|||||
Impact of restructuring and impairment: |
|||||||||||||
Restructuring and impairment |
18,369 |
51,870 |
48,493 |
51,870 |
|||||||||
Inventory write-off |
- |
6,656 |
26,905 |
6,656 |
|||||||||
Adjusted operating income |
$ |
45,828 |
$ |
78,846 |
$ |
186,245 |
$ |
292,518 |
|||||
Operating margin |
5.3 % |
3.0 % |
5.0 % |
8.7 % |
|||||||||
Operating margin, excluding restructuring impact |
8.8 % |
11.7 % |
8.4 % |
10.9 % |
|||||||||
Revenue |
$ |
522,340 |
$ |
673,436 |
$ |
2,225,659 |
$ |
2,695,669 |
|
||||||||||||
Three months ended |
Year ended |
|||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||
Provision (benefit) for income taxes |
$ |
(32,860) |
$ |
27,666 |
$ |
(15,808) |
$ |
85,193 |
||||
Impact of restructuring on provision for |
(903) |
(6,933) |
10,651 |
(6,933) |
||||||||
Impact of Tax Changes |
32,187 |
- |
32,187 |
- |
||||||||
Provision for income taxes, excluding |
$ |
(1,576) |
$ |
20,733 |
$ |
27,030 |
$ |
78,260 |
||||
Income before provision for income taxes |
24,355 |
18,436 |
88,970 |
232,459 |
||||||||
Impact of restructuring and impairment expense: |
||||||||||||
Inventory write-off |
- |
6,656 |
26,905 |
6,656 |
||||||||
Restructuring and impairment |
18,369 |
51,870 |
48,493 |
51,870 |
||||||||
Impact of charges associated with our Q4 |
||||||||||||
Unrealized investment loss |
- |
- |
9,009 |
- |
||||||||
Income before provision for income taxes, |
$ |
42,724 |
$ |
76,962 |
$ |
173,377 |
$ |
290,985 |
||||
Effective tax rate |
-134.9 % |
150.1 % |
-17.8 % |
36.6 % |
||||||||
Effective tax rate, excluding restructuring impact |
-3.7 % |
26.9 % |
15.6 % |
26.9 % |
|
||||||||||||
Three months ended |
Year ended |
|||||||||||
2022 |
2021 |
2022 |
2021 |
|||||||||
Net income |
$ |
57,215 |
$ |
(9,230) |
$ |
104,778 |
$ |
147,266 |
||||
Impact of restructuring and impairment expense: |
||||||||||||
Restructuring and impairment |
18,369 |
51,870 |
48,493 |
51,870 |
||||||||
Cost of sales - Restructuring |
- |
6,656 |
26,905 |
6,656 |
||||||||
Tax impact |
903 |
6,933 |
(9,566) |
6,933 |
||||||||
Impact of charges associated with our Q4 |
||||||||||||
Unrealized loss on investment |
- |
- |
9,009 |
- |
||||||||
Tax impact |
- |
- |
(1,085) |
- |
||||||||
Tax impact from method change |
(32,187) |
- |
(32,187) |
- |
||||||||
Adjusted net income |
$ |
44,300 |
$ |
56,229 |
$ |
146,347 |
$ |
212,725 |
||||
Diluted earnings per share |
$ |
1.15 |
$ |
(0.18) |
$ |
2.07 |
$ |
2.86 |
||||
Diluted earnings per share, excluding |
$ |
0.89 |
$ |
1.11 |
$ |
2.90 |
$ |
4.14 |
||||
Weighted-average common shares |
49,783 |
50,801 |
50,525 |
51,427 |
|
||||||||||||
Three months ended |
Year ended |
|||||||||||
2023 - Low-end |
2023 High-end |
2023 - Low-end |
2023 High-end |
|||||||||
Earnings Per Share |
$ |
0.17 |
$ |
0.27 |
$ |
2.27 |
$ |
2.67 |
||||
Impact of restructuring and impairment expense: |
||||||||||||
Restructuring and impairment |
0.10 |
0.10 |
0.10 |
0.10 |
||||||||
Tax impact |
(0.02) |
(0.02) |
(0.02) |
(0.02) |
||||||||
Adjusted EPS |
$ |
0.25 |
$ |
0.35 |
$ |
2.35 |
$ |
2.75 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/nu-skin-enterprises-reports-fourth-quarter-and-2022-financial-results-301748090.html
SOURCE
Media: media@nuskin.com, (801) 345-6397 OR Investors: investorrelations@nuskin.com, (801) 345-3577